Cargando…
肺部肿瘤热消融联合免疫治疗现状与进展
Recent studies have shown that tumor immune microenvironment is closely related to tumor progression, metastasis, recurrence and response to treatment. Some immunotherapies also offer hope for cancer patients. However, the efficacy of tumor immunotherapy is uncertain and has some side effects. In or...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051299/ https://www.ncbi.nlm.nih.gov/pubmed/35477191 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.09 |
_version_ | 1784696521162227712 |
---|---|
collection | PubMed |
description | Recent studies have shown that tumor immune microenvironment is closely related to tumor progression, metastasis, recurrence and response to treatment. Some immunotherapies also offer hope for cancer patients. However, the efficacy of tumor immunotherapy is uncertain and has some side effects. In order to enhance its efficacy, tumor immunotherapy combined with tumor thermal ablation has been studied. Thermal ablation has the advantages of minimally invasive, rapid recovery, safety, fewer complications, conformation, reliable effect, repeatable, low cost, and has become the fourth tumor treatment measure after surgery, radiotherapy, and drug therapy. It can directly kill tumor cells and modulate the immune system through a variety of mechanisms, although the corresponding mechanisms are not well understood, but combined tumor immunotherapy has been proposed to treat several solid malignancies. In this review, the current status and progress of thermal ablation combined with immunotherapy for lung tumor were reviewed, and further studies on the efficacy and safety of thermal ablation combined with immunotherapy were expected. |
format | Online Article Text |
id | pubmed-9051299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-90512992022-05-11 肺部肿瘤热消融联合免疫治疗现状与进展 Zhongguo Fei Ai Za Zhi 综述 Recent studies have shown that tumor immune microenvironment is closely related to tumor progression, metastasis, recurrence and response to treatment. Some immunotherapies also offer hope for cancer patients. However, the efficacy of tumor immunotherapy is uncertain and has some side effects. In order to enhance its efficacy, tumor immunotherapy combined with tumor thermal ablation has been studied. Thermal ablation has the advantages of minimally invasive, rapid recovery, safety, fewer complications, conformation, reliable effect, repeatable, low cost, and has become the fourth tumor treatment measure after surgery, radiotherapy, and drug therapy. It can directly kill tumor cells and modulate the immune system through a variety of mechanisms, although the corresponding mechanisms are not well understood, but combined tumor immunotherapy has been proposed to treat several solid malignancies. In this review, the current status and progress of thermal ablation combined with immunotherapy for lung tumor were reviewed, and further studies on the efficacy and safety of thermal ablation combined with immunotherapy were expected. 中国肺癌杂志编辑部 2022-04-20 /pmc/articles/PMC9051299/ /pubmed/35477191 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.09 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 肺部肿瘤热消融联合免疫治疗现状与进展 |
title | 肺部肿瘤热消融联合免疫治疗现状与进展 |
title_full | 肺部肿瘤热消融联合免疫治疗现状与进展 |
title_fullStr | 肺部肿瘤热消融联合免疫治疗现状与进展 |
title_full_unstemmed | 肺部肿瘤热消融联合免疫治疗现状与进展 |
title_short | 肺部肿瘤热消融联合免疫治疗现状与进展 |
title_sort | 肺部肿瘤热消融联合免疫治疗现状与进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051299/ https://www.ncbi.nlm.nih.gov/pubmed/35477191 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.09 |
work_keys_str_mv | AT fèibùzhǒngliúrèxiāoróngliánhémiǎnyìzhìliáoxiànzhuàngyǔjìnzhǎn |